![Louis Tamayo](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 383 706 $ al 31/07/2026
Louis Tamayo is Chief Financial Officer at Lexeo Therapeutics, Inc. since 2025.
Formerly, Mr. Tamayo was Senior Vice President – Operational Excellence at Siemens Healthineers AG from 2023 to 2024.
Education includes an undergraduate degree from Northeastern University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
LEXEO THERAPEUTICS, INC. 0,12 % | 18/08/2026 | 92.907 ( 0,12 % ) | 383 706 $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| LEXEO THERAPEUTICS, INC. | Director Financiero/CFO | 15/08/2025 |
| Empresas | Cargo | Fin |
|---|---|---|
| SIEMENS HEALTHINEERS AG | Corporate Officer/Principal | 01/10/2024 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Northeastern University
 Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Siemens Healthineers AG
 Siemens Healthineers AG Medical SpecialtiesHealth Technology Provides diagnostic imaging and computer related services | Health Technology |
Lexeo Therapeutics Inc
 Lexeo Therapeutics Inc BiotechnologyHealth Technology Develops gene therapy to treat genetic diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
